EGFR and cancer: The addition of these tumor types served two purposes: (1) Enlarging the dataset allows identifying patient-specific altered signaling signatures with increased resolution, and (2) GBM, LUAD and LUSC are EGFR-overexpressing cancers, while SKCM tumors generally less express EGFR 21,22.